Neurogene
Xiaoyun Xu has a diverse work experience spanning various scientific roles. Most recently, they have been working as a Scientist, Analytical at Neurogene Inc. since March 2022. Prior to that, they were with Lonza from 2018 to 2022, where they held multiple roles including Scientist, Senior QC Analyst, QC Analyst IV, and QC Analyst III.
Xiaoyun's earlier experiences include working as a Research Associate at Houston Methodist from 2012 to 2018. Before that, they were a Postdoctoral Fellow at The University of Texas Health Science Center at Houston (UTHealth) from 2010 to 2011 and again from 2009 to 2009.
Throughout their career, Xiaoyun has gained valuable scientific expertise and experience in analytical science, quality control analysis, and research in various research institutions and pharmaceutical companies.
Xiaoyun Xu completed a Bachelor's degree in Polymer/Plastics Engineering at the University of Science and Technology of China from 1998 to 2003. After that, they pursued a Doctor of Philosophy degree in Chemistry at the University of Utah from 2003 to 2008.
This person is not in any offices
Neurogene
Neurogene was founded to bring life-changing medicines to patients and families affected by rare neurological disorders. We partner with leading academic researchers, patient advocacy organizations and caregivers to bring to patients therapies that address the underlying genetic cause of a broad spectrum of neurological diseases where no effective treatment options exist today. Our lead programs use AAV-based gene therapy technology to deliver a normal gene to patients with a dysfunctional gene. Neurogene is also investing in novel technology to develop treatments for diseases not well served by gene therapy.